• Explore /
  • Poster
  • / Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.

Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.

Abstract Poster

Authors

null

Emre Koca

Houston Methodist Hospital, Houston, TX

Emre Koca , Polly Ann Niravath , Joe Ensor Jr., Tejal Amar Patel , Xiaoxian Li , Pej Hemati , Helen Wong , Wei Qian , Toniva Boone , Jing Zhao , Priya V. Ramshesh , Adam Louis Cohen , Asha Murthy , Sindhu Nair , Jorge German Darcourt , Anna Belcheva , Virginia G. Kaklamani , Jenny Chee Ning Chang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT02988986

Citation

J Clin Oncol 37, 2019 (suppl; abstr 584)

DOI

10.1200/JCO.2019.37.15_suppl.584

Abstract #

584

Poster Bd #

76

Abstract Disclosures

Similar Posters

First Author: Ning Li

First Author: Ahmed Omar Kaseb

First Author: Amelia Bruce Zelnak

First Author: Steven R. Alberts